Nearly a year after new sickle cell gene therapies were approved, CNBC's Bertha Coombs reports a small number of patients are ...

The Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

On a family vacation, 14-year-old Jaden Hartley discovered he needed a heart transplant after experiencing this symptom. Now ...

As treatment and care continues to evolve, we must ensure that people living with this disease are able to advocate for ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Simmie White is taking control of her own story. The six-year-old girl and her mother want others to understand more about ...

Scott Turner Department of Housing and Urban Development secretary, announced a new Department of Government Efficiency Task ...

“We still have a serious challenge with sickle cell disease, which contributes to 20% of under-five mortality every year.

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.